How The BioCryst Pharmaceuticals (BCRX) Narrative Is Shifting With Astria Deal And FY26 Targets [Yahoo! Finance]
BioCryst Pharmaceuticals, Inc. (BCRX)
Last biocryst pharmaceuticals, inc. earnings: 3/5 07:05 am
Check Earnings Report
US:NASDAQ Investor Relations:
biocryst.gcs-web.com/investor-relations
Company Research
Source: Yahoo! Finance
BioCryst Pharmaceuticals' fair value estimate sits at US$21.30, with the latest update keeping this price target unchanged. Analysts linking this figure to reiterated FY26 revenue guidance, the completed Astria Therapeutics acquisition, and expectations around Orladeyo and pipeline assets are effectively signaling that their core thesis is intact, even as they debate execution risk and timelines. As you read on, you will see how these moving pieces shape the evolving analyst story around BioCryst and what to watch next. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value BioCryst Pharmaceuticals. What Wall Street Has Been Saying ?? Bullish Takeaways Wedbush raised its BioCryst price target to US$22 from US$21 and maintained an Outperform rating, tying its view to reiterated FY26 guidance, peak revenue targets and a commercial business that it describes as operating smoothly. Evercore ISI resumed coverage with
Show less
Read more
Impact Snapshot
Event Time:
BCRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCRX alerts
High impacting BioCryst Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
BCRX
News
- BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer [Yahoo! Finance]Yahoo! Finance
- BioCryst Appoints Sandeep M. Menon Chief Research and Development OfficerGlobeNewswire
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- BioCryst Pharmaceuticals, Inc. (BCRX) A Good Stock To Buy Now? [Yahoo! Finance]Yahoo! Finance
- BioCryst: The Buyout Rumor Is Noise, The Franchise Is Real [Seeking Alpha]Seeking Alpha
BCRX
Earnings
- 2/26/26 - Beat
BCRX
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/24/26 - Form 4
- 3/20/26 - Form 144
- BCRX's page on the SEC website